NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $7,171,000 | +3398.0% | 530,800 | +4556.1% | 0.17% | +2716.7% |
| Q3 2021 | $205,000 | +10.8% | 11,400 | +4.7% | 0.01% | -14.3% |
| Q4 2020 | $185,000 | -76.5% | 10,892 | -70.2% | 0.01% | -89.9% |
| Q4 2019 | $788,000 | +203.1% | 36,528 | +156.1% | 0.07% | +187.5% |
| Q3 2019 | $260,000 | -38.8% | 14,264 | +19.4% | 0.02% | -38.5% |
| Q2 2019 | $425,000 | -49.0% | 11,944 | -72.0% | 0.04% | -77.5% |
| Q2 2017 | $833,000 | – | 42,600 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |